CHARNELL HOLLIS: Open Payments
NPI 1922883883 · PASADENA, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,195 in 189 payments from 17 companies in 2025. Trend: 2023 $398 · 2024 $1,690 · 2025 $4,195
Food & beverage: $4,195
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 44 | $825 |
| Madrigal Pharmaceuticals | 27 | $708 |
| Janssen Biotech, Inc. | 19 | $509 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 34 | $494 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $434 |
| Celltrion USA Inc. | 8 | $221 |
| Gilead Sciences, Inc. | 10 | $212 |
| Aimmune Therapeutics, Inc. | 7 | $163 |
| Ardelyx, Inc. | 7 | $145 |
| Braintree Laboratories, Inc. | 6 | $140 |
Products named: REZDIFFRA, TREMFYA, XIFAXAN, RINVOQ, ENTYVIO, VEGZELMA, SKYRIZI, LINZESS.
Industry payments across TX — which companies pay providers there.
